Xofluza PMS

Xofluza Tablets drug use-results survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223826

Enrollment

3000

Registered

2018-02-27

Start date

2018-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza A or B virus infection

Interventions

investigational material(s) Generic name etc : Xofluza Tablets INN of investigational material : Baloxavir Marboxil Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Inve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Influenza A or B virus infection patients

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety, Efficacy	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026